Literature DB >> 9533476

In-vitro activities of paromomycin and lasalocid evaluated in combination against Cryptosporidium parvum.

X You1, R F Schinazi, M J Arrowood, M Lejkowski, A S Juodawlkis, J R Mead.   

Abstract

Using a chemiluminescence immunoassay, paromomycin and lasalocid were shown to inhibit Cryptosporidium parvum growth in Madin-Darby canine kidney cells in a concentration-dependent manner. The median effective concentrations (EC50s) for paromomycin and lasalocid were 1184 mg/L and 0.4 mg/L, respectively. Neither drug was cytotoxic to host cells at concentrations up to five times their EC50s. Drug combination studies were conducted and the resulting data were analysed by the median-effect principle and combination index method. Statistically significant synergy was observed when combinations of paromomycin and lasalocid were used at ratios of 5000:1 and 2500:1. A possible mechanism for synergy is discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9533476     DOI: 10.1093/jac/41.2.293

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

Review 1.  In vitro cultivation of cryptosporidium species.

Authors:  Michael J Arrowood
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

2.  Efficacy of ginkgolic acids against Cryptosporidium andersoni in cell culture.

Authors:  Liang Wu; Xu-gan Jiang; Yu-juan Shen; Zhao-xi Lu; Guo-hua Tu; Xing-li Fu; Sheng-xia Chen; Jian-ping Cao
Journal:  Parasitol Res       Date:  2011-05-10       Impact factor: 2.289

3.  Characterization of an intestinal epithelial cell receptor recognized by the Cryptosporidium parvum sporozoite ligand CSL.

Authors:  R C Langer; D A Schaefer; M W Riggs
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

4.  Polyether ionophores: broad-spectrum and promising biologically active molecules for the control of drug-resistant bacteria and parasites.

Authors:  Dion A Kevin Ii; Damaris Af Meujo; Mark T Hamann
Journal:  Expert Opin Drug Discov       Date:  2009-02       Impact factor: 6.098

5.  Effect of select medium supplements on in vitro development of Cryptosporidium andersoni in HCT-8 cells.

Authors:  Liang Wu; Sheng-xia Chen; Xu-gan Jiang; Yu-juan Shen; Zhao-xi Lu; Guo-hua Tu; Xing-li Fu; Jian-ping Cao
Journal:  Parasitol Res       Date:  2009-07-30       Impact factor: 2.289

6.  Optimization of the Urea Linker of Triazolopyridazine MMV665917 Results in a New Anticryptosporidial Lead with Improved Potency and Predicted hERG Safety Margin.

Authors:  Edmund Oboh; Tanner J Schubert; Jose E Teixeira; Erin E Stebbins; Peter Miller; Emily Philo; Haresh Thakellapalli; Scott D Campbell; David W Griggs; Christopher D Huston; Marvin J Meyers
Journal:  J Med Chem       Date:  2021-08-03       Impact factor: 8.039

7.  A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box.

Authors:  R S Jumani; K Bessoff; M S Love; P Miller; E E Stebbins; J E Teixeira; M A Campbell; M J Meyers; J A Zambriski; V Nunez; A K Woods; C W McNamara; C D Huston
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.